<DOC>
	<DOCNO>NCT01120600</DOCNO>
	<brief_summary>The purpose study test hypothesis treatment odanacatib result increase BMD ( bone mineral density ) compare treatment placebo . This study also evaluate safety efficacy odanacatib male osteoporosis patient .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Odanacatib ( MK-0822 ) Men With Osteoporosis ( MK-0822-053 )</brief_title>
	<detailed_description>The original study divide two part , primary analysis endpoint occur 24 month patient remain study additional 12 month ( Part 2 ) . Amendment 1 protocol remove additional 12 month period Month 36 BMD analysis delete .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Has osteoporosis Has anatomy suitable dual energy xray absorptiometry ( DXA ) scan lumbar spine hip Is ambulatory Is currently oral bisphosphonates treatment osteoporosis Had previous hip fragility fracture candidate standard care therapy Has fragility fracture ( vertebral nonvertebral fracture indicate reduce bone strength ) within 12 month Has one previous vertebral fracture Has diagnose metabolic bone disorder osteoporosis Is Vitamin D deficient Has history renal stone Has active parathyroid disease Has history thyroid disease well control medication Is diagnose secondary osteoporosis Has daily calcium intake &lt; 1,200 mg unwilling take study prescribe supplement increase dietary intake , daily calcium intake least 1200 mg Has history malignancy â‰¤5 year prior sign inform consent Has diagnose hypogonadism due cause affect multiple organ body system</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>